Dr. Katherine Fuh is a gynecologic oncologist who specializes in diagnosing and managing cancers of the female reproductive system, including advanced ovarian and uterine cancers. Her expertise includes chemotherapy, targeted therapy and immunotherapy.
Fuh earned her medical degree at Georgetown University School of Medicine. She completed a residency in obstetrics and gynecology at Stanford University, where she also earned a doctorate in cancer biology. She completed a fellowship in gynecologic oncology through a joint program of UCSF and Stanford Medicine.
As a physician-scientist, Fuh studies how to improve outcomes for patients with ovarian or uterine cancer. She is nationally known for her use of molecular biomarkers (measurable biological indicators of disease) to guide and personalize therapy. Her laboratory focuses on identifying biomarkers associated with treatment resistance in patients with ovarian cancer and developing targeted therapies to overcome the resistance. She has been involved in numerous clinical trials (studies that use human volunteers to evaluate promising treatments) and is the principal investigator for one of the first clinical trials of a new drug for patients with treatment-resistant metastatic ovarian cancer. She is also the principal investigator on multiple research projects that received grants from various federal funders and foundations. She has published many scientific papers on gynecologic cancers, and her research has advanced how doctors approach treating these diseases.
Prior to joining UCSF, Fuh was a faculty member at Washington University School of Medicine in St. Louis. In addition to directing translational and basic research there, she was an integral member of the division of gynecologic cancer and the cancer center.
Georgetown University School of Medicine, MD, 2005
Stanford University, Obstetrics and Gynecology, 2009
Stanford University, Gynecologic Oncology, 2012